AbbVie Inc (ABBV) has declared a quarterly dividend of $1.64 per share, payable to shareholders of record. The ex-dividend date is set for October 14, 2025, meaning investors must own shares before this date to qualify for the dividend payment. Eligible shareholders will receive the payment on November 13, 2025.
The current dividend yield stands at 2.80%. AbbVie has a consistent track record of providing dividends, reflecting its commitment to returning value to shareholders. As of November 20, 2025, the company's market capitalization is $411.6 billion, with a price-to-earnings (P/E) ratio of 172.38 and earnings per share (EPS) of 1.35.
AbbVie is a research-based biopharmaceutical company headquartered in North Chicago, Illinois, employing 55,000 full-time staff. The company focuses on the development and sale of pharmaceutical products across various therapeutic areas, including Immunology, Oncology, Aesthetics, and Neuroscience.
The upcoming earnings report is scheduled for July 29, 2026, with an estimated EPS of $3.71 and revenue of $17.0 billion, further underscoring the company's financial health and operational performance.
This update provides insight into AbbVie's cash flow generation and capital allocation strategy, which may appeal to income-focused investors. However, it is important to note that dividends are not guaranteed and can be adjusted based on business performance and management decisions.